Cellular Biomedicine Group (CBMG) Earns Coverage Optimism Rating of 0.29
News articles about Cellular Biomedicine Group (NASDAQ:CBMG) have been trending positive on Tuesday, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cellular Biomedicine Group earned a coverage optimism score of 0.29 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.7530430821711 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of Cellular Biomedicine Group (NASDAQ:CBMG) remained flat at $11.00 during mid-day trading on Tuesday. The stock had a trading volume of 7,933 shares. Cellular Biomedicine Group has a 12-month low of $5.05 and a 12-month high of $15.45. The firm’s 50-day moving average price is $9.42 and its 200 day moving average price is $9.41. The firm’s market capitalization is $155.19 million.
Cellular Biomedicine Group declared that its board has authorized a stock repurchase plan on Thursday, June 1st that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the biotechnology company to purchase shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.
Separately, Maxim Group set a $18.00 price target on Cellular Biomedicine Group and gave the stock a “buy” rating in a research note on Tuesday, August 29th.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China.
Receive News & Stock Ratings for Cellular Biomedicine Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group Inc. and related stocks with our FREE daily email newsletter.